235 related articles for article (PubMed ID: 27809600)
21. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma.
Iwasaki T; Hamano T; Ogata A; Hashimoto N; Kitano M; Kakishita E
Br J Haematol; 2002 Mar; 116(4):796-802. PubMed ID: 11886383
[TBL] [Abstract][Full Text] [Related]
22. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.
Rapezzi C; Merlini G; Quarta CC; Riva L; Longhi S; Leone O; Salvi F; Ciliberti P; Pastorelli F; Biagini E; Coccolo F; Cooke RM; Bacchi-Reggiani L; Sangiorgi D; Ferlini A; Cavo M; Zamagni E; Fonte ML; Palladini G; Salinaro F; Musca F; Obici L; Branzi A; Perlini S
Circulation; 2009 Sep; 120(13):1203-12. PubMed ID: 19752327
[TBL] [Abstract][Full Text] [Related]
23. Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.
Badar T; Cornelison AM; Shah ND; Bashir Q; Parmar S; Patel K; Hosing C; Popat U; Weber DM; Thomas SK; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH
Eur J Haematol; 2016 Oct; 97(4):342-7. PubMed ID: 26773409
[TBL] [Abstract][Full Text] [Related]
24. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response.
Grogan M; Dispenzieri A; Gertz MA
Heart; 2017 Jul; 103(14):1065-1072. PubMed ID: 28456755
[TBL] [Abstract][Full Text] [Related]
25. Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis.
Halushka MK; Eng G; Collins AB; Judge DP; Semigran MJ; Stone JR
J Cardiovasc Transl Res; 2015 Jun; 8(4):264-8. PubMed ID: 25925232
[TBL] [Abstract][Full Text] [Related]
26. Cardiac amyloidosis: updates in diagnosis and management.
Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
[TBL] [Abstract][Full Text] [Related]
27. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis.
Ng B; Connors LH; Davidoff R; Skinner M; Falk RH
Arch Intern Med; 2005 Jun; 165(12):1425-9. PubMed ID: 15983293
[TBL] [Abstract][Full Text] [Related]
28. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.
Palladini G; Campana C; Klersy C; Balduini A; Vadacca G; Perfetti V; Perlini S; Obici L; Ascari E; d'Eril GM; Moratti R; Merlini G
Circulation; 2003 May; 107(19):2440-5. PubMed ID: 12719281
[TBL] [Abstract][Full Text] [Related]
29. Use of biomarkers to diagnose and manage cardiac amyloidosis.
Castiglione V; Franzini M; Aimo A; Carecci A; Lombardi CM; Passino C; Rapezzi C; Emdin M; Vergaro G
Eur J Heart Fail; 2021 Feb; 23(2):217-230. PubMed ID: 33527656
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study.
Mohty D; Boulogne C; Magne J; Varroud-Vial N; Martin S; Ettaif H; Fadel BM; Bridoux F; Aboyans V; Damy T; Jaccard A
Eur Heart J Cardiovasc Imaging; 2016 Sep; 17(9):961-9. PubMed ID: 27194782
[TBL] [Abstract][Full Text] [Related]
31. Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry).
Tuzovic M; Kobayashi Y; Wheeler M; Barrett C; Liedtke M; Lafayette R; Schrier S; Haddad F; Witteles R
Am J Cardiol; 2017 Oct; 120(8):1381-1386. PubMed ID: 28844519
[TBL] [Abstract][Full Text] [Related]
32. Plasma Hepatocyte Growth Factor for Diagnosis and Prognosis in Light Chain and Transthyretin Cardiac Amyloidosis.
Zhang KW; Miao J; Mitchell JD; Alvarez-Cardona J; Tomasek K; Su YR; Gordon M; Cornell RF; Lenihan DJ
JACC CardioOncol; 2020 Mar; 2(1):56-66. PubMed ID: 33283202
[TBL] [Abstract][Full Text] [Related]
33. LGE Provides Incremental Prognostic Information Over Serum Biomarkers in AL Cardiac Amyloidosis.
Boynton SJ; Geske JB; Dispenzieri A; Syed IS; Hanson TJ; Grogan M; Araoz PA
JACC Cardiovasc Imaging; 2016 Jun; 9(6):680-6. PubMed ID: 27209101
[TBL] [Abstract][Full Text] [Related]
34. [The prognostic value of baseline serum free light chain in cardiac amyloidosis].
Zhao L; Tian Z; Fang Q
Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):186-90. PubMed ID: 26926369
[TBL] [Abstract][Full Text] [Related]
35. Prevalence, Severity, and Prognostic Value of Sleep Apnea Syndromes in Cardiac Amyloidosis.
Bodez D; Guellich A; Kharoubi M; Covali-Noroc A; Tissot CM; Guendouz S; Hittinger L; Dubois-Randé JL; Lefaucheur JP; Planté-Bordeneuve V; Adnot S; Boyer L; Damy T
Sleep; 2016 Jul; 39(7):1333-41. PubMed ID: 27091529
[TBL] [Abstract][Full Text] [Related]
36. Amyloidosis in Heart Failure.
Ihne S; Morbach C; Obici L; Palladini G; Störk S
Curr Heart Fail Rep; 2019 Dec; 16(6):285-303. PubMed ID: 31782077
[TBL] [Abstract][Full Text] [Related]
37. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
[TBL] [Abstract][Full Text] [Related]
38. [Cardiac amyloidosis: a case series of 14 patients, description and prognosis].
Isabel C; Georgin-Lavialle S; Aouba A; Delarue R; Nochy D; Karras A; Azarine A; Hermine O; Ranque B; Hagège A; Pouchot J
Rev Med Interne; 2013 Nov; 34(11):671-8. PubMed ID: 24090573
[TBL] [Abstract][Full Text] [Related]
39. Cardiac Care of Patients with Cardiac Amyloidosis.
Itzhaki Ben Zadok O; Kornowski R
Acta Haematol; 2020; 143(4):343-351. PubMed ID: 32408301
[TBL] [Abstract][Full Text] [Related]
40. Outcome of patients with cardiac amyloidosis admitted to an intensive care unit for acute heart failure.
d'Humières T; Fard D; Damy T; Roubille F; Galat A; Doan HL; Oliver L; Dubois-Randé JL; Squara P; Lim P; Ternacle J
Arch Cardiovasc Dis; 2018 Oct; 111(10):582-590. PubMed ID: 29709420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
